"Zemanov\u00E1, Milada" . "1"^^ . . . "I" . "2" . . "Lung cancer is the leading cause of death among malignant tumours, most patients presenting in the metastatic stage IV. Therapy of this stage consists mainly in systemic palliative treatment. The required standard for all adenocarcinomas includes investigation to determine the molecular profile of activating EGFR mutations as targeted treatment with some of the small molecule tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib) in patients with positivity of this mutation results in approximately 60% response rate and significantly extended survival. Afatinib is a new selective irreversible inhibitor not only of EGFR, but of the whole ErbB family. Two randomized trials of afatinib have shown significantly better efficacy in terms of higher rates of treatment responses and extended progression- -free survival in the range of 11.1-13.8 months as determined according to predefined diagnostic subgroups, as compared with a standard platinum-based cytostatic combination. Based on these results, it was approved for administration to EGFR TKI-na\u00EFve patients with non-small- -cell lung carcinoma with activating mutations of the epidermal growth factor receptor (EGFR). Ongoing studies compare afatinib with other TKI EGFRs."@en . "Farmakoterapie" . . . . "RIV/00216208:11110/14:10287139" . . "10" . "Afatinib as first-line therapy of advanced lung cancer"@en . "Afatinib v 1. linii l\u00E9\u010Dby pokro\u010Dil\u00E9ho plicn\u00EDho karcinomu"@cs . . "Afatinib v 1. linii l\u00E9\u010Dby pokro\u010Dil\u00E9ho plicn\u00EDho karcinomu" . . . "Afatinib v 1. linii l\u00E9\u010Dby pokro\u010Dil\u00E9ho plicn\u00EDho karcinomu" . "Plicn\u00ED karcinom je hlavn\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na zhoubn\u00E9 n\u00E1dory, p\u0159i\u010Dem\u017E v\u011Bt\u0161ina nemocn\u00FDch p\u0159ich\u00E1z\u00ED s metastatick\u00FDm stadiem IV. V tomto stadiu spo\u010D\u00EDv\u00E1 terapie hlavn\u011B v paliativn\u00ED syst\u00E9mov\u00E9 l\u00E9\u010Db\u011B. Standardem u v\u0161ech adenokarcinom\u016F by m\u011Blo b\u00FDt vy\u0161et\u0159en\u00ED molekul\u00E1rn\u00EDho profilu aktiva\u010Dn\u00EDch mutac\u00ED EGFR, proto\u017Ee p\u0159i pozitivit\u011B t\u00E9to mutace vede c\u00EDlen\u00E1 l\u00E9\u010Dba n\u011Bkter\u00FDm z n\u00EDzkomolekul\u00E1rn\u00EDch tyrosinkin\u00E1zov\u00FDch inhibitor\u016F (gefitinib, erlotinib, afatinib) k dosa\u017Een\u00ED p\u0159ibli\u017En\u011B 60 % l\u00E9\u010Debn\u00FDch odpov\u011Bd\u00ED a v\u00FDznamn\u011B prodlu\u017Euje p\u0159e\u017Eit\u00ED. Afatinib je nov\u00FD selektivn\u00ED ireverzibiln\u00ED inhibitor nejen EGFR, ale cel\u00E9 rodiny ErbB. Ve dvou randomizovan\u00FDch studi\u00EDch prok\u00E1zal v\u00FDznamn\u011B lep\u0161\u00ED \u00FA\u010Dinnost ve smyslu vy\u0161\u0161\u00EDho po\u010Dtu l\u00E9\u010Debn\u00FDch odpov\u011Bd\u00ED a prodlou\u017Een\u00ED doby do progrese v rozmez\u00ED 11,1-13,8 m\u011Bs\u00EDce, podle p\u0159eddefinovan\u00FDch diagnostick\u00FDch podskupin, v porovn\u00E1n\u00ED se standardn\u00ED cytostatickou kombinac\u00ED zalo\u017Eenou na cisplatin\u011B. Na z\u00E1klad\u011B toho byl registrov\u00E1n k pod\u00E1v\u00E1n\u00ED u nemocn\u00FDch s nemalobun\u011B\u010Dn\u00FDm plicn\u00EDm karcinomem s aktiva\u010Dn\u00EDmi mutacemi receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) dosud nel\u00E9\u010Den\u00FDch inhibitory tyrosinkin\u00E1zy EGFR. Prob\u00EDhaj\u00ED studie srovn\u00E1vaj\u00EDc\u00ED afatinib s jin\u00FDmi inhibitory tyrosinkin\u00E1zy EGFR."@cs . . "Plicn\u00ED karcinom je hlavn\u00ED p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED na zhoubn\u00E9 n\u00E1dory, p\u0159i\u010Dem\u017E v\u011Bt\u0161ina nemocn\u00FDch p\u0159ich\u00E1z\u00ED s metastatick\u00FDm stadiem IV. V tomto stadiu spo\u010D\u00EDv\u00E1 terapie hlavn\u011B v paliativn\u00ED syst\u00E9mov\u00E9 l\u00E9\u010Db\u011B. Standardem u v\u0161ech adenokarcinom\u016F by m\u011Blo b\u00FDt vy\u0161et\u0159en\u00ED molekul\u00E1rn\u00EDho profilu aktiva\u010Dn\u00EDch mutac\u00ED EGFR, proto\u017Ee p\u0159i pozitivit\u011B t\u00E9to mutace vede c\u00EDlen\u00E1 l\u00E9\u010Dba n\u011Bkter\u00FDm z n\u00EDzkomolekul\u00E1rn\u00EDch tyrosinkin\u00E1zov\u00FDch inhibitor\u016F (gefitinib, erlotinib, afatinib) k dosa\u017Een\u00ED p\u0159ibli\u017En\u011B 60 % l\u00E9\u010Debn\u00FDch odpov\u011Bd\u00ED a v\u00FDznamn\u011B prodlu\u017Euje p\u0159e\u017Eit\u00ED. Afatinib je nov\u00FD selektivn\u00ED ireverzibiln\u00ED inhibitor nejen EGFR, ale cel\u00E9 rodiny ErbB. Ve dvou randomizovan\u00FDch studi\u00EDch prok\u00E1zal v\u00FDznamn\u011B lep\u0161\u00ED \u00FA\u010Dinnost ve smyslu vy\u0161\u0161\u00EDho po\u010Dtu l\u00E9\u010Debn\u00FDch odpov\u011Bd\u00ED a prodlou\u017Een\u00ED doby do progrese v rozmez\u00ED 11,1-13,8 m\u011Bs\u00EDce, podle p\u0159eddefinovan\u00FDch diagnostick\u00FDch podskupin, v porovn\u00E1n\u00ED se standardn\u00ED cytostatickou kombinac\u00ED zalo\u017Eenou na cisplatin\u011B. Na z\u00E1klad\u011B toho byl registrov\u00E1n k pod\u00E1v\u00E1n\u00ED u nemocn\u00FDch s nemalobun\u011B\u010Dn\u00FDm plicn\u00EDm karcinomem s aktiva\u010Dn\u00EDmi mutacemi receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) dosud nel\u00E9\u010Den\u00FDch inhibitory tyrosinkin\u00E1zy EGFR. Prob\u00EDhaj\u00ED studie srovn\u00E1vaj\u00EDc\u00ED afatinib s jin\u00FDmi inhibitory tyrosinkin\u00E1zy EGFR." . "RIV/00216208:11110/14:10287139!RIV15-MSM-11110___" . "1796" . "Afatinib v 1. linii l\u00E9\u010Dby pokro\u010Dil\u00E9ho plicn\u00EDho karcinomu"@cs . . "4"^^ . "[15068D8C0B97]" . . "1801-1209" . "11110" . . "CZ - \u010Cesk\u00E1 republika" . . "Afatinib as first-line therapy of advanced lung cancer"@en . "1"^^ . "tyrosine kinase inhibitor; epidermal growth factor receptor (EGFR); afatinib; Non-small-cell lung carcinoma (NSCLC)"@en .